MX2019010941A - Receptores de antigeno y usos de los mismos. - Google Patents

Receptores de antigeno y usos de los mismos.

Info

Publication number
MX2019010941A
MX2019010941A MX2019010941A MX2019010941A MX2019010941A MX 2019010941 A MX2019010941 A MX 2019010941A MX 2019010941 A MX2019010941 A MX 2019010941A MX 2019010941 A MX2019010941 A MX 2019010941A MX 2019010941 A MX2019010941 A MX 2019010941A
Authority
MX
Mexico
Prior art keywords
antigen receptors
treatment
antigen
diseases
receptors
Prior art date
Application number
MX2019010941A
Other languages
English (en)
Inventor
Simon Petra
Sahin Ugur
Birtel Matthias
Holger VOSS Ralf
Caspar Janina
Original Assignee
Biontech Cell & Gene Therapies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Cell & Gene Therapies Gmbh filed Critical Biontech Cell & Gene Therapies Gmbh
Publication of MX2019010941A publication Critical patent/MX2019010941A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
    • A61K2239/30—Mixture of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención generalmente abarca el tratamiento de enfermedades al dirigir células que expresan un antígeno en la superficie celular. En particular, la invención se refiere a receptores de antígeno recombinante y usos de los mismos. Las células T diseñadas para expresar tales receptores de antígeno son útiles en el tratamiento de enfermedades caracterizadas por la expresión de uno o más antígenos unidos por los receptores de antígeno.
MX2019010941A 2017-03-15 2018-03-14 Receptores de antigeno y usos de los mismos. MX2019010941A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2017/056086 WO2018166589A1 (en) 2017-03-15 2017-03-15 Antigen receptors and uses thereof
PCT/EP2018/056399 WO2018167151A1 (en) 2017-03-15 2018-03-14 Antigen receptors and uses thereof

Publications (1)

Publication Number Publication Date
MX2019010941A true MX2019010941A (es) 2019-12-19

Family

ID=58360981

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010941A MX2019010941A (es) 2017-03-15 2018-03-14 Receptores de antigeno y usos de los mismos.

Country Status (15)

Country Link
US (1) US11702631B2 (es)
EP (1) EP3596113B1 (es)
JP (1) JP7073417B2 (es)
KR (1) KR102396925B1 (es)
CN (1) CN110621693B (es)
AU (1) AU2018234068B2 (es)
BR (1) BR112019018705A2 (es)
CA (1) CA3054253A1 (es)
ES (1) ES2886189T3 (es)
IL (1) IL269213B2 (es)
MX (1) MX2019010941A (es)
NZ (1) NZ756383A (es)
SG (1) SG11201907715YA (es)
WO (2) WO2018166589A1 (es)
ZA (1) ZA201905441B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023078431A1 (zh) * 2021-11-05 2023-05-11 清华大学 一种特异性结合间皮素的合成t细胞受体抗原受体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3409577A (en) 1966-07-06 1968-11-05 Owens Corning Fiberglass Corp Method of detackifying tacky resins
US6534633B1 (en) * 1998-10-21 2003-03-18 Altor Bioscience Corporation Polyspecific binding molecules and uses thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2690825C (en) * 2007-05-11 2019-02-12 Altor Bioscience Corporation Fusion molecules and il-15 variants
EP2502934B1 (en) * 2011-03-24 2018-01-17 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Single chain antigen recognizing constructs (scARCs) stabilized by the introduction of novel disulfide bonds
WO2016180467A1 (en) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
EP3770168A1 (en) 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2017059900A1 (en) * 2015-10-07 2017-04-13 Biontech Cell & Gene Therapies Gmbh Antigen receptors and uses thereof

Also Published As

Publication number Publication date
WO2018166589A1 (en) 2018-09-20
IL269213A (en) 2019-11-28
WO2018167151A1 (en) 2018-09-20
AU2018234068A1 (en) 2019-09-05
IL269213B2 (en) 2023-11-01
ZA201905441B (en) 2020-11-25
SG11201907715YA (en) 2019-09-27
CN110621693B (zh) 2024-01-12
RU2019125594A3 (es) 2021-06-09
KR102396925B1 (ko) 2022-05-13
JP2020509783A (ja) 2020-04-02
EP3596113B1 (en) 2021-08-04
US20200063101A1 (en) 2020-02-27
AU2018234068B2 (en) 2021-10-21
RU2019125594A (ru) 2021-04-15
JP7073417B2 (ja) 2022-05-23
KR20190128683A (ko) 2019-11-18
ES2886189T3 (es) 2021-12-16
CN110621693A (zh) 2019-12-27
IL269213B1 (en) 2023-07-01
BR112019018705A2 (pt) 2020-04-07
EP3596113A1 (en) 2020-01-22
NZ756383A (en) 2023-03-31
US11702631B2 (en) 2023-07-18
CA3054253A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
MX2018004121A (es) Receptores de antigeno y usos de los mismos.
PH12019500750A1 (en) Chimeric antigen receptors for the treatment of cancer
PH12018502113A1 (en) Chimeric receptors and methods of use thereof
MX2021013336A (es) Anticuerpos y receptores de antigeno quimericos especificos para cd19.
PH12018502118A1 (en) Chimeric receptors to flt3 and methods of use thereof
MY189028A (en) Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
MX2019006598A (es) Celulas asesinas naturales modificadas geneticamente y sus usos.
MX2022004082A (es) Anticuerpos biespecificos contra cd3 y cd20.
MX2017001013A (es) Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1.
PH12020551671A1 (en) Chimeric receptors to dll3 and methods of use thereof
EP4219689A3 (en) Immune effector cell therapies with enhanced efficacy
MX2017001008A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
MY181834A (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
UY35468A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
EP3593812A3 (en) Treatment of cancer using chimeric antigen receptor
MX2016008076A (es) Receptores quimericos de antigeno de mesotelina humana y uso de los mismos.
SG10201806108TA (en) Binding proteins and methods of use thereof
MX2019002903A (es) Receptores de antigeno quimerico que comprenden dominios de tipo iii de fibronectina especificos del bcma y usos de estos.
AU2015279552A8 (en) Neural cells expressing adenovirus E4ORF1, and methods of making and using the same
PH12021550120A1 (en) Chimeric receptors to steap1 and methods of use thereof
PH12019550194A1 (en) Anti-ceacam1 antibody and use thereof
MX2019010941A (es) Receptores de antigeno y usos de los mismos.
NZ731491A (en) Cd83 binding proteins and uses thereof